Accurate Biogene is a comprehensive, easy to use life science search engine for life scientists, researchers, graduate students, and health professionals.
Saturday, January 17th, 2009 has been chosen as our interview date for
out of state students interested in our training program. If you are a
superior MS IV, who is interested in a strong program, in a great
location, save the date to interview with us.
Health
Canada has just approved Xarelto® (rivaroxaban) for the prevention of
venous thromboembolic events (VTE) in patients who have undergone
elective total hip or total knee replacement surgery. This marks the first approval for Xarelto worldwide.
For
the first time in the world, the new oral, once-daily anticoagulant
Xarelto is to be made commercially available to patients in Canada
In
July 2008, the CHMP issued a positive opinion and recommended approval
of rivaroxaban in the EU for the prevention of venous blood clots in
patients undergoing elective total hip or total knee replacement
surgery. A final decision is expected very soon
Xarelto is the most studied oral, direct Factor Xa inhibitor in the world today
Xarelto
is being jointly developed by Bayer HealthCare and Johnson &
Johnson Pharmaceutical Research & Development, L.L.C.
I find it interesting that so often athletes are dissuaded from pursuing aggressive treatment regimes for their injuries when at times an aggressive path to recovery can improve outcomes and reduce the likelihood of a need for surgical intervention.
The Department of Orthopaedics & Sports Medicine at the University
of South Florida College of medicine is seeking a talented physician to
expand in the area of Hand surgery at the rank of Assistant Professor
or Associate Professor. This position will direct hand sub-specialty
education for the USF Orthopaedic Residency Training Program.
NovaBone Products LLC (NBP) has released a new form of the synthetic bone graft, NovaBone Putty® (bone graft substitute). "Surgeons now have a synthetic that handles more easily," said Arthur Wotiz, CEO of NovaBone Products. "NovaBone
Bioactive Synthetic Graft is the only bone graft substitute that has
been proven to signal, recruit, proliferate and differentiate
osteoblasts.
If you have some orthopedic news that you would like to share with the Orthogate community, please register/login and submit your news, event, article, announcement or review from the Submit Content menu in your Members Area. Join now .
News
NovaBone Products LLC (NBP) has released a new form of the synthetic bone graft, NovaBone Putty® (bone graft substitute). "Surgeons now have a synthetic that handles more easily," said Arthur Wotiz, CEO of NovaBone Products. "NovaBone
Bioactive Synthetic Graft is the only bone graft substitute that has
been proven to signal, recruit, proliferate and differentiate
osteoblasts.
We subscribe to the HONcode principles. Verify here